Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

RPG Life Sciences Limited

NSE: RPGLIFEPharmaceuticals

Share price

₹2,811.70

-2.80% close of 8 Oct 2026

Market cap ₹4,569 CrP/E 39.1

Business score

How strong the business is, in one number. The parts behind it are in Pro.

62

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹4,569 Cr

P/E ratio

39.1

P/B ratio

7.7

ROCE

25.7%

ROE

19.4%

Dividend yield

0.8%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹3,089.2052-week low ₹1,744.00

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 11.8% over the past year, and 9.3% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 19.6% to 21.1% over the last four years.

Whether it grew faster than its sector

It grew 9.3% a year against a sector median of 13.1% — 3.8 percentage points slower.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

It has no steady three-year profit record yet, so growth cannot be weighed against the price.

Profit growthPrice per ₹1 profitPer 1% growth
RPG Life Sciences Limited — this one—39.1×—
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 20 of 130 on returns, 76 of 127 on growth, 50 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 25.7% on capital, ahead of 85% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Only 2 years of matching accounts on file — too few to judge this yet.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 8 checks clear · 88%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 28 Jul 2026 · Consolidated · Unaudited

Revenue

₹196 Cr

Revenue vs last year

+15.8%

Revenue vs last quarter

+10.6%

Net profit

₹31 Cr

Profit vs last year

+18.3%

Profit vs last quarter

+2.5%

Net margin

15.7%

EPS

₹18.60

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹4,569 Cr
Prev close
₹2,811.70
52w High
₹3,128
52w Low
₹1,733
Enterprise value
₹4,313 Cr
Beta
1.0
Price CAGR 1y
28.0%
Price CAGR 3y
32.0%
Price CAGR 5y
33.0%
Price CAGR 10y
19.0%

Ratios

Return on assets
14.5%
PEG ratio
—
P/E ratio
39.1
P/B ratio
7.7
EV / EBITDA
27.8
Industry P/E
38.0
ROCE
25.7%
ROCE 5y average
26.0%
ROE
19.4%
Debt / Equity
0.0
Interest coverage
78.0
Dividend yield
0.8%
ROE 3y average
—
ROE last year
19.0%

Annual P&L

Annual revenue
₹708 Cr
Annual profit
₹115 Cr
Operating margin
21.0%
Net profit margin
16.2%
EBITDA margin
20.9%
Sales growth 3y
—
Sales growth 5y
—
Profit growth 3y
—
Profit growth 5y
—
EPS
₹69.6
Sales growth TTM
8.0%
Profit growth TTM
-5.0%
Dividend payout
34.0%

Quarter P&L

Sales latest quarter
₹196 Cr
Profit latest quarter
₹31 Cr
YoY quarterly sales growth
15.8%
YoY quarterly profit growth
19.2%
OPM latest quarter
22.1%

Balance Sheet

Book Value
₹372
Face Value
₹8.0
Total debt
₹20 Cr
Total cash
₹192 Cr
Borrowings
₹20 Cr
Reserves / Equity
45.5

Cash Flow

Operating cash flow
₹56 Cr
Free cash flow
-₹9 Cr
FCF yield
-0.2%
Net cash flow
₹122 Cr

Shareholding

Promoter holding
73.0%
FII holding
0.9%
DII holding
8.7%
Public holding
17.4%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,757.5533.34,21,6950.902,901.26.015,299.910.520.5
Divi's Lab.9,457.6084.32,51,0700.31902.065.53,080.027.822.0
Torrent Pharma.4,630.4578.91,76,1270.81566.05.84,921.054.915.2
Zydus Lifesci.1,115.8022.91,11,3020.09990.2-35.18,017.022.021.1
Laurus Labs2,019.0099.81,09,0890.10362.1125.52,026.329.117.8
Cipla1,301.8529.41,05,1730.98785.6-39.27,119.32.315.5
Mankind Pharma2,397.6046.499,0320.04574.129.64,030.612.913.5
RPG LifeScience.2,841.3540.24,6990.8330.817.0195.715.825.7
Median416.5034.12,1180.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales148154154127165172173143169182180177196
Expenses124118133143140144152
Material Cost353638
Change in Inventories-141.53-9.06
Purchases of Stock-in-Trade442340
Employee Cost353638
Other Expenses404746
Operating Profit49253539403343
OPM %22242516242728182121221922
Other Income3115516-5145
Exceptional items (within Other Income)-8.421.100
Interest0000001
Depreciation5555566
Profit before tax471353549294041
Tax %26132625242626
Net Profit351172637223031
EPS in Rs21711622131819
Diluted EPS in Rs131819

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2025Mar 2026TTM
Sales653708734
Expenses493560579
Material Cost136
Change in Inventories-22
Purchases of Stock-in-Trade138
Employee Cost141
Other Expenses167
Operating Profit161148155
OPM %252121
Other Income952929
Exceptional items (within Other Income)3.90
Interest221
Depreciation212122
Profit before tax233154160
Tax %2125
Net Profit183115120
EPS in Rs1117072
Diluted EPS in Rs70
Dividend Payout %2234

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
—
3 years
—
TTM
8%

Compounded profit growth

10 years
—
5 years
—
3 years
—
TTM
-5%

Stock price CAGR

10 years
19%
5 years
33%
3 years
32%
1 year
28%

Return on equity

10 years
—
5 years
—
3 years
—
Last year
19%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2025Mar 2026
Equity Capital1313
Reserves517592
Borrowings020
Other Liabilities127168
Total Liabilities658793
Fixed Assets172197
CWIP1623
Investments12785
Other Assets343488
Total Assets658793

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2025Mar 2026
Cash from Operating Activity7857
Cash from Investing Activity-4286
Cash from Financing Activity-27-21
Net Cash Flow9122
Free Cash Flow151-9.36

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2025Mar 2026
Debtor Days4860
Inventory Days159179
Days Payable135141
Cash Conversion Cycle7299
Working Capital Days4564
ROCE %26

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters737373737373737373737373
FIIs0.460.560.901.151.351.301.461.351.1110.870.95
DIIs1.571.772.162.615.456.066.146.496.707.047.458.68
Public252524232020191919191917
No. of Shareholders21,08821,86622,13722,23223,48124,89124,86725,83226,65725,90525,28223,886

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +24.0% (₹2,267.80 → ₹2,811.70)Brick size ₹140.54 (fixed)Bricks 17
₹2,000₹2,500₹3,000₹2,812Jan '26Jun '26
Price moved up one brickPrice moved down one brickLast close ₹2,811.70 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-256inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

51,83,016inr

2026-03-31

News

News and filings about RPG Life Sciences Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Threonine
  • Tryptophan
  • packaging material
  • pharmaceutical raw materials & intermediates

manages assets for

Sells to

  • CENABAST, Chile · branded/generic pharmaceutical formulations (govt tender)

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE105J01010

Plants

  • API Manufacturing Plant
  • Formulation Plant F1 · Ankleshwar, Gujarat
  • Formulation Plant F2 · Ankleshwar, Gujarat

News impact

Big market events that reach RPG Life Sciences Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

9 Jul 2026unspecified₹24
27 Jun 2025unspecified₹20
27 Jun 2025special₹4
28 Jun 2024unspecified₹16
21 Jul 2023unspecified₹12
14 Jul 2022unspecified₹9.6
13 Aug 2021unspecified₹7.2
24 Mar 2020interim₹4

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
30 Apr 2026NK SECURITIES RESEARCH PRIVATE LIMITEDBUY1,09,801₹2,257.02
30 Apr 2026NK SECURITIES RESEARCH PRIVATE LIMITEDSELL1,09,801₹2,258.73

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.